Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
P/E ratio for Solid Biosciences Inc. (SLDB)
P/E ratio as of 2023: -1.27
According to Solid Biosciences Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.27. At the end of 2022 the company had a P/E ratio of -0.70.
P/E ratio history for Solid Biosciences Inc. from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.27 |
| 2022 | -0.70 |
| 2021 | -2.59 |
| 2020 | -4.37 |
| 2019 | -1.55 |
| 2018 | -11.92 |
| 2017 | -13.99 |
| 2016 | -20.20 |
| 2015 | -68.22 |